Mirvie RNA test aims to predict pregnancy complications

Pregnancy may lower Long COVID risk, with researchers linking immune changes to reduced symptoms, though some groups remain vulnerable.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

A new study reported how a soluble fms-like tyrosine kinase-1 to placental growth factor ratio can help predict preeclampsia progression, aiding in risk assessment and optimizing patient care.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The 2025 Canadian Postpartum Guidelines recommend at least 120 minutes of weekly exercise, daily pelvic floor training, and improved sleep hygiene to enhance maternal and infant health.